Discovery of Potent and Selective Quinazoline-Based LATS1/2 Inhibitors Promoting Hepatic Regeneration

Therapeutic acceleration of endogenous liver regeneration remains a considerable unmet need for patients with acute or chronic liver injury. Among the pathways that coordinate regenerative responses, the Hippo pathway and its main components LATS1/2 kinases play a critical role by limiting YAP-dependent transcriptional programs associated with regeneration. Pharmacological inhibition of LATS1/2 thus represents a strategy to activate hepatic YAP signaling and promote tissue repair. Herein, we report the discovery of quinazoline-based LATS1/2 inhibitors derived from VT-02956 (1). Structure−activity relationship studies identified compound 24, a single-digit nanomolar LATS1/2 inhibitor with improved cellular YAP activation and metabolic stability. Compound 24 showed favorable kinase selectivity (S(35) = 0.04) and improved pharmacokinetics. In a partial hepatectomy mouse model, intraperitoneal administration of 24 activated YAP signaling, as evidenced by the upregulation of Cyr61 and Ankrd1, and significantly enhanced hepatocyte proliferation. These findings establish a medicinal chemistry foundation for developing LATS1/2 inhibitors as therapeutic agents for hepatic regeneration.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-19
DOI
https://doi.org/10.1021/acs.jmedchem.6c01827
Primary Topic
Hippo pathway signaling and YAP/TAZ
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of Potent and Selective Quinazoline-Based LATS1/2 Inhibitors Promoting Hepatic Regeneration

Na Young Lee, Byumseok Koh, Ja Hyun Koo, Nam‐Chul Cho et al.
Journal of Medicinal Chemistry
Hippo pathway signaling and YAP/TAZ
article

Discovery of Potent and Selective Quinazoline-Based LATS1/2 Inhibitors Promoting Hepatic Regeneration

Na Young Lee, Byumseok Koh, Ja Hyun Koo, Nam‐Chul Cho, Hongjun Jeon, Seokwoo Lee, Eui Jin Lee, Anagha Reneesh, 오예주, Minji Kang, Sunjoo Ahn
article en

Abstract

Therapeutic acceleration of endogenous liver regeneration remains a considerable unmet need for patients with acute or chronic liver injury. Among the pathways that coordinate regenerative responses, the Hippo pathway and its main components LATS1/2 kinases play a critical role by limiting YAP-dependent transcriptional programs associated with regeneration. Pharmacological inhibition of LATS1/2 thus represents a strategy to activate hepatic YAP signaling and promote tissue repair. Herein, we report the discovery of quinazoline-based LATS1/2 inhibitors derived from VT-02956 (1). Structure−activity relationship studies identified compound 24, a single-digit nanomolar LATS1/2 inhibitor with improved cellular YAP activation and metabolic stability. Compound 24 showed favorable kinase selectivity (S(35) = 0.04) and improved pharmacokinetics. In a partial hepatectomy mouse model, intraperitoneal administration of 24 activated YAP signaling, as evidenced by the upregulation of Cyr61 and Ankrd1, and significantly enhanced hepatocyte proliferation. These findings establish a medicinal chemistry foundation for developing LATS1/2 inhibitors as therapeutic agents for hepatic regeneration.

Journal of Medicinal Chemistry
Seoul National University (KR), Chungnam National University (KR), Korea Research Institute of Chemical Technology (KR), Korea University of Science and Technology (KR)
Hippo pathway signaling and YAP/TAZ
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon